Information  X 
Enter a valid email address

SkinBioTherapeutics (SBTX)

  Print   

Tuesday 22 March, 2022

SkinBioTherapeutics

Investor Presentation - Interim Financial Results

RNS Number : 6051F
SkinBioTherapeutics PLC
22 March 2022
 

22 March 2022

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Investor Presentation - Interim Financial Results

 

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that Stuart Ashman, CEO, & Doug Quinn, CFO, will provide an update to investors on the Company's interim financial results via the Investor Meet Company platform on 29th March 2022 at 09:00am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet SkinBioTherapeutics plc via:

https://www.investormeetcompany.com/skinbiotherapeutics-plc/register-investor

Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.

 

For more information please contact:

SkinBioTherapeutics plc

Stuart J . Ashman, CEO

Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson, Dale Bellis (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Nathan Billis 

Tel: +44 (0) 20 7457 2020

[email protected]

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit: www.skinbiotix.com .

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAPPUQAWUPPGUP

a d v e r t i s e m e n t